8.46

5.16% -0.46

Engene Holdings Inc (ENGN)

Overview News Price History Financials Discussions Forecast

Engene Holdings Inc stock is traded at $8.46, with a volume of 316.18K. It is down -5.16% in the last 24 hours and down -2.53% over the past month. enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Previous Close:

$8.92

Open:

$8.91

24h Volume:

316.18K

Relative Volume:

0.26

Market Cap:

$565.74M

Revenue:

Net Income/Loss:

$-103.21M

P/E Ratio:

-1.8391

EPS:

-4.6001

Net Cash Flow:

$-26.70M

1W Performance:

+4.83%

1M Performance:

-2.53%

6M Performance:

+160.31%

1Y Performance:

+28.38%

1-Day Range:

$8.20

$9.14

1-Week Range:

$7.75

$9.14

52-Week Range:

$2.65

$11.14

Engene Holdings Inc Stock (ENGN) Company Profile

Name

Engene Holdings Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

(514) 332-4888

Address

4868 RUE LEVY, SUITE 220, SAINT-LAURENT

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ENGN's Discussions on Twitter

Compare ENGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENGN Engene Holdings Inc	8.46	596.50M	0	-103.21M	-26.70M	-4.6001
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-11-25	Upgrade	Raymond James	Outperform → Strong Buy
Feb-18-25	Initiated	Piper Sandler	Overweight
Feb-14-25	Downgrade	UBS	Buy → Neutral
Dec-23-24	Initiated	H.C. Wainwright	Buy
Nov-27-24	Initiated	Raymond James	Outperform
Nov-18-24	Initiated	JMP Securities	Mkt Outperform
Aug-28-24	Initiated	Oppenheimer	Outperform
Apr-22-24	Initiated	Wells Fargo	Overweight
Apr-15-24	Initiated	Guggenheim	Buy
Mar-28-24	Initiated	UBS	Buy
Mar-08-24	Initiated	Morgan Stanley	Overweight
Feb-20-24	Initiated	Leerink Partners	Outperform

View All

Engene Holdings Inc Stock (ENGN) Latest News

Dec 12, 2025

enGene (NASDAQ:ENGN) Stock Price Up 8.2%Time to Buy? - MarketBeat

Dec 12, 2025

Dec 11, 2025

enGene (ENGN) Projected to Post Earnings on Thursday - MarketBeat

Dec 11, 2025

Dec 10, 2025

Holdings of enGene Holdings Inc (ENGN) are aligned with the stars - setenews.com

Dec 10, 2025

Dec 08, 2025

Market Recap: Can enGene Holdings Inc Equity Warrant stock attract ESG capital inflowsQuarterly Earnings Summary & Smart Money Movement Alerts - moha.gov.vn

Dec 08, 2025

Dec 06, 2025

How enGene Holdings Inc. stock performs in rate cut cyclesJuly 2025 Rallies & Long Hold Capital Preservation Plans - Newser

Dec 04, 2025

Dec 03, 2025

H.C. Wainwright maintains Buy rating on Engene stock as detalimogene joins FDA pilot program By Investing.com - Investing.com South Africa

Dec 03, 2025

H.C. Wainwright maintains Buy rating on Engene stock as detalimogene joins FDA pilot program - Investing.com Nigeria

Dec 03, 2025

Franklin Resources Inc. Sells 136,866 Shares of enGene Holdings Inc. $ENGN - MarketBeat

Dec 03, 2025

9 Best Up and Coming Canadian Stocks to Buy - Insider Monkey

Dec 03, 2025

Dec 02, 2025

FDA selects enGene’s bladder cancer therapy for development program By Investing.com - Investing.com Australia

Dec 02, 2025

enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readines - pharmiweb.com

Dec 02, 2025

enGene stock rises after FDA selects bladder cancer therapy for CMC pilot program - Investing.com Nigeria

Dec 02, 2025

Engene's detalimogene selected for FDA manufacturing pilot program to support manufacturing readiness - marketscreener.com

Dec 02, 2025

FDA selects enGene’s bladder cancer therapy for development program - Investing.com

Dec 02, 2025

enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness - Yahoo Finance

Dec 02, 2025

What valuation multiples suggest for enGene Holdings Inc. Equity Warrant stockEarnings Performance Report & Risk Managed Investment Entry Signals - Newser

Dec 02, 2025

Nov 28, 2025

Can enGene Holdings Inc. Equity Warrant stock attract ESG capital inflowsForecast Cut & AI Optimized Trading Strategy Guides - moha.gov.vn

Nov 28, 2025

enGene Holdings Inc Stock Analysis and ForecastHealthcare Stock Analysis & Learn the Secrets of Pro Traders - earlytimes.in

Nov 28, 2025

Nov 27, 2025

enGene (NASDAQ:ENGN) Trading Up 6.9%Should You Buy? - MarketBeat

Nov 27, 2025

enGene Holdings Prices $130 Million Public Offering to Advance Genetic Medicine Programs - MSN

Nov 27, 2025

Nov 25, 2025

enGene to Present at Piper Sandler Healthcare Conference - TipRanks

Nov 25, 2025

enGene to Present at the Piper Sandler 37th Annual Healthcare Conference - Markets Financial Content

Nov 25, 2025

Nov 24, 2025

PERCEPTIVE ADVISORS LLC's Strategic Acquisition in enGene Holdings Inc. - GuruFocus

Nov 24, 2025

Investors in cash trouble should check out enGene Holdings Inc (ENGN) - setenews.com

Nov 24, 2025

Nov 22, 2025

What drives enGene Holdings Inc Equity Warrant stock priceDebt-to-Equity Ratio Analysis & High Return Trading Ideas - earlytimes.in

Nov 22, 2025

Nov 21, 2025